DVAX

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines. The company's proprietary CpG 1018 adjuvant technology enhances immune responses and is used in its lead product HEPLISAV-B, a hepatitis B vaccine approved in the United States and Europe. Dynavax's adjuvant technology has applications in vaccines for infectious diseases and cancer immunotherapy. The company is developing additional vaccine candidates targeting diseases with significant unmet medical needs. Dynavax has licensing partnerships with other pharmaceutical companies to incorporate its adjuvant technology into their vaccine programs.